Status:
RECRUITING
Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Osteoporosis, Postmenopausal
Eligibility:
FEMALE
50+ years
Phase:
NA
Brief Summary
This study aims to follow a cohort of osteoporotic patients treated with anti-osteoporotic drugs and to evaluate the impact of these treatments on the osteoporosis-cardiovascular-sarcopenia triad and ...
Detailed Description
Exploratory study involving functional explorations in longitudinal follow-up, initiated in parallel with a treatment indicated in the patient's usual care and management. The main objective is the e...
Eligibility Criteria
Inclusion
- Women aged 50 years or older with postmenopausal osteoporosis, whether fractured or not, requiring initiation of treatment with antiosteoporotic drugs (bisphosphonates, raloxifene, teriparatide, denosumab and others to come for this indication, including romosozumab), either orally or by injection, as part of their care and management.
- Able to give informed consent to participate in research.
- Affiliation to a Social Security system.
Exclusion
- Patient with chronic renal failure, defined as glomerular filtration rate \< 30 mL.min-1 estimated by CKD-EPI.
- Patient with a medical and/or surgical history deemed by the investigator or his/her representative to be incompatible with the trial.
- Patient under legal protection or deprived of liberty.
- Refusal to participate.
Key Trial Info
Start Date :
February 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05228262
Start Date
February 15 2022
End Date
February 1 2027
Last Update
October 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Clermont-Ferrand
Clermont-Ferrand, France, 63000